{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-038733","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.596533+00:00","generated_at":"2026-06-12T04:20:11.369598+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Stoke Therapeutics Q2 2023 net loss $30.7M; cash $231.4M to fund operations to end of 2025","bullets":["Net loss $30.7M ($0.69 per share) vs $24.7M ($0.63) in Q2 2022; R&D expenses $20.6M.","Cash and marketable securities $231.4M as of June 30, 2023; expected runway to end of 2025.","Revenue reversed $(2.5)M vs $3.2M a year ago due to $5.3M cumulative catch-up on Acadia collaboration.","STK-001: additional data from MONARCH/ADMIRAL and OLEs expected Q1 2024 to inform Phase 3 design.","STK-002: UK MHRA authorized Phase 1 OSPREY study for ADOA; enrollment in FALCON natural history completed (n=48)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-038733","json":"https://secwatch.observer/filing/0000950170-23-038733.json","markdown":"https://secwatch.observer/filing/0000950170-23-038733.md","text":"https://secwatch.observer/filing/0000950170-23-038733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000095017023038733/0000950170-23-038733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000095017023038733/stok-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:20:11.369598+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8c3e7e19b7b62c80262fbf12da8740176d19cf9f","claim":"Stoke Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 7, 2023, Stoke Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1623526/000095017023038733/0000950170-23-038733-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}